Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]F-RESCA-G5 is a radiopharmaceutical agent used for positron emission tomography (PET) imaging, particularly in immunoPET applications targeting the digestive system and hepatocellular carcinoma. It is synthesized by direct labeling of heat-sensitive biomolecules with fluorine-18 (^18F) using the Al^18^F-RESCA method, which employs an aluminum fluoride restrained complexing agent (RESCA) as a chelator. This approach allows efficient and mild radiolabeling of peptides, proteins, or engineered antibody fragments at room temperature in aqueous conditions. The resulting compound enables high-resolution PET imaging due to the favorable physical properties of ^18F, such as its short half-life and high positron yield. The technology was developed by academic groups specializing in radiopharmaceutical research at institutions including the University of Leuven and Vrije Universiteit Brussel[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [18F]F-RESCA-G5.